How Researchers Discovered a Black Licorice Compound for IBD: A Step-by-Step Guide

Introduction

Inflammatory bowel disease (IBD) affects millions worldwide, causing chronic intestinal inflammation, pain, and tissue damage. Traditional treatments often have limited efficacy or side effects. However, researchers recently made a breakthrough using a stem cell-based model of the human intestine to screen thousands of compounds. They discovered that glycyrrhizin—a natural compound found in black licorice—shows strong anti-inflammatory potential. This guide walks through the step-by-step research process, so you can understand how scientists uncovered this promising candidate and consider replicating or building upon their methods.

What You Need

• Human induced pluripotent stem cells (iPSCs) or adult intestinal stem cells – to grow intestinal organoids (mini-guts) in the lab.
• Matrigel or other extracellular matrix – for 3D culture support.
• Growth factors and media (e.g., EGF, Noggin, R-spondin) – to maintain stem cell identity and differentiation.
• Compound library – including thousands of natural and synthetic molecules (e.g., Glycyrrhiza glabra extract or pure glycyrrhizin).
• High-throughput screening (HTS) equipment – automated liquid handlers, plate readers for viability and inflammation markers.
• Mouse models of IBD (e.g., dextran sulfate sodium-induced colitis) – for in vivo validation.
• Lab-grown human intestinal tissue (organoids or biopsies) – for ex vivo testing.
• Cell death and inflammation assays (e.g., LDH release, cytokine ELISA, TUNEL staining).

Step-by-Step Guide

Step 1: Develop a Stem Cell-Based Intestinal Model

Begin by reprogramming human skin or blood cells into induced pluripotent stem cells (iPSCs) or directly isolate adult intestinal stem cells. Culture them in 3D Matrigel droplets with optimized media to form intestinal organoids. These mini-guts recapitulate the crypt-villus structure, contain enterocytes, goblet cells, and other relevant cell types. Validate the model by confirming expression of intestinal markers (e.g., Villin, Lgr5, Muc2). This step is crucial because the model must mimic human IBD pathophysiology for reliable compound screening.

Step 2: Induce an IBD-Like Inflammatory State

Expose the intestinal organoids to pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) or to a cocktail that mimics the IBD microenvironment. Alternatively, use genetic approaches (e.g., knockouts of barrier genes) to predispose the tissue to inflammation. Confirm the model displays key features: increased cell death, decreased barrier integrity, and elevated inflammatory cytokines. This step creates a baseline diseased state against which compounds can be tested.

Step 3: High-Throughput Compound Screening

Using automated liquid handling, add your compound library to the inflamed organoids in multi-well plates. Include positive controls (e.g., dexamethasone) and negative controls (vehicle only). After 24–72 hours, measure cell viability via ATP assays (CellTiter-Glo) and inflammatory markers via secreted cytokine quantification (e.g., IL-8, TNF-α). For each compound, calculate a Z-score to rank efficacy. In the original study, researchers tested thousands of compounds and identified glycyrrhizin as a top hit.

Step 4: Identify and Prioritize Glycyrrhizin

From the screen, pick compounds that significantly reduce cell death and inflammation without causing toxicity. Glycyrrhizin emerged as a strong candidate: it is a natural saponin from licorice root, known for anti-viral and anti-inflammatory properties. Validate the hit by repeating the assay with fresh compound at multiple concentrations to establish an EC50. Also quench autofluorescence or interference by using orthogonal assays (e.g., RNA sequencing for pathway analysis).

Step 5: Validate in Lab-Grown Human Intestinal Tissue

Take the validated compound and test it in fresh human intestinal organoids and also in intact biopsies from IBD patients (if available). Treat tissues with glycyrrhizin and measure reduction in cell death (e.g., LDH release, caspase activation) and inflammation (e.g., IL-1β levels, NF-κB signaling). The original study found that glycyrrhizin reduced intestinal damage and cell death compared to untreated samples.

Step 6: Test in an In Vivo Mouse Model of IBD

Induce colitis in mice using DSS or TNBS, then administer glycyrrhizin orally or intraperitoneally (dose ranging from 10–100 mg/kg daily). Monitor disease activity index (weight loss, stool consistency, bleeding) and colon length. At sacrifice, analyze histological damage (H&E staining) and markers of apoptosis (TUNEL). The mice treated with glycyrrhizin showed less colon shortening, reduced mucosal injury, and fewer apoptotic cells, supporting the compound's therapeutic potential.

Step 7: Interpret Results and Plan Next Steps

Compare data across models. If glycyrrhizin consistently reduces inflammation and tissue damage, consider further pharmacokinetic studies (e.g., bioavailability, metabolism) and safety toxicology. Because black licorice contains glycyrrhizin in high amounts, note potential side effects (e.g., hypertension with chronic use). Future steps may involve chemical modifications to improve efficacy and safety, or combination therapies. The stem cell model can now be used to screen for other compounds or to test patient-specific responses.

Tips for Success

• Use patient-derived stem cells – if possible, obtain iPSCs or organoids from IBD patients to capture genetic and epigenetic aspects of the disease.
• Include toxicity counterscreens – administer compounds on healthy control organoids to ensure selectivity for inflamed tissue.
• Validate with multiple endpoints – complement viability assays with RNA-seq, proteomics, and barrier function tests (e.g., FITC-dextran permeability).
• Consider the compound's natural source – glycyrrhizin is abundant in licorice, but pure compound is better for reproducibility; watch for glycyrrhetinic acid metabolites.
• Scale up slowly – start with a small pilot screen (100–200 compounds) to troubleshoot conditions before running thousands.
• Collaborate with clinicians – early involvement of gastroenterologists can help align the model with human disease features and eventual clinical translation.

By following these steps, researchers can efficiently discover novel IBD treatments from natural sources. The stem cell-based platform described here not only identified glycyrrhizin but also paves the way for personalized medicine and drug repurposing efforts.